 Annexon Inc NASDAQ: ANNX has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy GA. GA, also known as atrophic age-related macular degeneration AMD or dry AMD, can lead to blindness caused by damaged and dying retinal cells. 